drugset / Trial / NCT02903836
Phase II Study of Oral Nafithromycin in CABP
RandomizedFactorialQuadruple-blindTreatment
Summary
Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
Timeline
- Start
- 2016-11-18
- Primary completion
- 2017-07
- Completion
- 2017-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Nafithromycin | Small molecule | 800 mg | Oral |